SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Medical - Healthcare >

Manhattan Scientifics, Inc. (MHTX)

Add MHTX Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 3/27/2017 7:40:16 PM - Followers: 71 - Board type: Free - Posts Today: 0

Our company

The Company's business model capitalizes on inventions and technology from which profits are created through licensing. MSI is dedicated to earning profit for its 8,600 shareholders by identifying, supporting, patenting and marketing technical innovation by harvesting top technology talent to bring game-changing product to the market. We emphasize novel technology in the Nanomedicine space with the potential to be disruptive and the ability to establish sustainable businesses.

We are "patient capital" with experienced business building partners who bring the perspective of merchant bankers, not venture capitalists. Our approach to assist scientists to commercialize their work is by providing a forum within which the commercialization process is fostered through partnerships with existing companies (Fortune/1000 or larger). The entrepreneurial scientists and engineers who join us create personal success and wealth on an accelerated basis by virtue of ownership of publicly traded Manhattan Scientifics shares (OTC BB: MHTX).


Technology : Advenced Materials


Manhattan Scientifics has acquired the exclusive rights to the key patents and IP and will soon be positioned to enter into manufacturing and licensing agreements.

Nano Titanium

Manhattan Scientific's nanostructured metal technology is based on over 16 years of highly focused research and development. Nanostructured metals and alloys possess significantly enhanced mechanical properties that include, for example, increased strength without concurrent losses in ductility, and significantly increased resistance to fatigue fracture. Nanostructured commercially pure grades of titanium have proven to also possess excellent machinability as well as high toughness and strength. Manhattan Scientifics has developed unique processing methodology for producing nanostructures in a wide range of ductile metals and alloys and is now commercializing this new and revolutionary technology.

Enhanced strength and fatigue resistance

Nanostructured metals and alloys offer many advantages for a wide range of structural applications. Application areas include biomedical structures, sports structures, aerospace and chemical structures, among others.

Technology : Nanomedecine


Manhattan Scientifics and Senior Scientific, LLC have announced that they have begun cooperative work to commercialize Senior Scientific's nano medicine cancer detection technology. Manhattan Scientifics acquired Senior Scientific, along with all its patents and IP in the emerging field of nano medicine; specifically Dr. Flynn's work in biomagnetic detection of cancer and other diseases through magnetic field sensors. These sensors make it possible to identify and image small clusters of cancer cells substantially increasing the sensitivity for finding cancer at an earlier stage than is currently available, and without the use of ionizing radiation or large magnetic fields. The biomagnetic sensor method is applicable to breast, ovarian, leukemia, prostate, melanoma, and other cancers. Dr. Flynn's research has been funded by the National Institute of Health (NIH). Management intends to identify one or more appropriate Fortune/500 industrial partners in the Big Pharma group to bring product to the market under royalty bearing licenses.

To learn more about Senior Scientific and the technologies being developed, please visit

About Nanomedicine

The term "Nanomedicine" is commonly used to describe the convergence of nanotechnology and pharmacology. It has been defined as "the science and technology of diagnosing, treating, and preventing disease and traumatic injury, or relieving pain, and of preserving and improving human health, using molecular tools and molecular knowledge of the human body" by the European Science Foundation. (European Science Foundation)

Nanomedicine will soon be used for diagnosing and treating cancer, musculoskeletal and inflammatory diseases, neurodegenerative diseases, diabetes and infectious diseases. In general, nanotechnology has the incredible potential to improve patient outcomes. What does this mean? Patients will be living longer with a greater quality of life!

In the fight against cancer, nanotechnology introduces unique approaches to diagnosis and treatment that could not even be imagined with conventional technology. New tools engineered at sizes much smaller than a human cell will enable researchers and clinicians to detect cancer earlier, treat it with much greater precision and fewer side effects, and possibly stop the disease long before it can do any damage.

Understanding Nanotechnology

Nanotechnology is the development and engineering of devices so small that they are measured on a molecular scale. This emerging field involves scientists from many different disciplines, including physicists, chemists, engineers, information technologists, and material scientists, as well as biologists. Nanotechnology is being applied to almost every field imaginable, including electronics, magnetics, optics, information technology, materials development and biomedicine.

The Size of Things

Nanoscale devices are one hundred to ten thousand times smaller than human cells. They are similar in size to large biological molecules ("biomolecules") such as enzymes and receptors. As an example, hemoglobin, the molecule that carries oxygen in red blood cells, is approximately 5 nanometers in diameter. Nanoscale devices smaller than 50 nanometers can easily enter most cells, while those smaller than 20 nanometers can move out of blood vessels as they circulate through the body.

Because of their small size, nanoscale devices can readily interact with biomolecules on both the surface and inside cells. By gaining access to so many areas of the body, they have the potential to detect disease and deliver treatment in ways unimagined before now.

Authorized Shares: 950 million -- As of March 3, 2014
There were 489,383,252 shares of common stock issued and outstanding as of March 21, 2014 (per 2013 10K).

Current SEC Filings: Click Here

All releases/news from official MHTX releases, unless noted

Pushing the Limits of Cancer Detection

(June 10, 2014) ALBUQUERQUE, N.M.-- Manhattan Scientifics, Inc. (OTCQB: MHTX) announced today that it has delivered its break-through, cancer measurement instrument to The University of Texas M.D. Anderson Cancer Center in Houston, TX. Full release

PrecisionMRX™ Nanoparticle Production Process Ready

(April 14, 2014) Building upon local relationships, Senior Scientific is stepping into the commercial space with first product introductions through Azano Biotech. Azano currently supplies research reagents to the same cancer researchers who will eventually be customers for the MRX II instrument. Full release

Progress on our First Major Product: the NanoMRXII

(March 19, 2014) The overarching mission for February has been to get the 9 Channel System up and running. We are delighted to be delivering this extraordinary device to our collaborators at MD Anderson. Full release

Manhattan Scientifics Announces Commercial Introduction Of NanoMRX Precision Nanoparticles

(March 18, 2014) ALBUQUERQUE, N.M. -- Manhattan Scientifics (OTCQB: MHTX) announced today a collaboration with Azano Biotech that will make NanoMRX Precision Nanoparticles available for purchase. Full release

MHTX Announces Collaboration with MD Anderson Cancer Center

(January 27, 2014) ALBUQUERQUE, N.M.--Manhattan Scientifics (OTC: MHTX) executed an agreement to collaborate with The University of Texas MD Anderson Cancer Center (MDACC) to advance, demonstrate and validate a breakthrough technology developed by Edward R. Flynn, PhD, for the very early detection of cancer. Dr. Flynn is the founder and chief scientist of MHTX’s subsidiary, Senior Scientific LLC. Senior Scientific is seeking to commercialize this patented non-invasive technology using ultra-sensitive magnetic detectors to locate, identify and measure tumors thousands of times smaller than detectable using current technologies. Full release

MHTX Announces Initiation of Coverage by Independent Equity Research Firm SeeThruEquity, LLC

(October 1, 2013) New York, NY – Manhattan Scientifics Inc. (OTCQB: MHTX) announced today that SeeThruEquity, LLC has initiated coverage on the Company. The report is now available for viewing at the following link.  Full release

MHTX Announces the Engagement of Loraine Upham to Market Its Cancer Diagnostic Technology

(August 23, 2013) Manhattan Scientifics announced today that Loraine Upham has been engaged as a consultant to support its cancer team. The technology, developed by Edward R. Flynn, PhD, provides the most specific and most sensitive method for detecting cancer currently known. Full release

Senior Scientific Announces Issuance of U.S. Patent

(May 23, 2013) Senior Scientific, LLC, a unit of Manhattan Scientifics and a developer of molecular imaging and nanobiotechnology for the early detection and localization of cancer and other human diseases, today announced that the United States Patent Office (USPTO) has issued U.S. Patent No. 8,447,379 entitled "Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof." Full release

Manhattan Scientifics Announces Receipt of $2.5M Commitment to Build Breakthrough Cancer Detection

(April 9, 2013) NEW YORK--Manhattan Scientifics announced today that it has received the initial $1 million of a $2.5 million commitment to build the first generation of its advanced cancer detection devices. Full release

Interview with mobile phone inventor Marty Cooper

(April 3, 2013) The first mobile phone call was made 40 years ago today, on 3 April 1973. Martin Cooper, at the time a senior engineer at Motorola and now a member of our Science and Technology Committee, called a rival colleague at another telecoms company and announced he was speaking from "a 'real' cell telephone". Full release

Cancer Research: NFCR Cites MHTX’s Early Cancer Detection Tech as Research Breakthrough for 2012

(January 7, 2013) ALBUQUERQUE, N.M.--The National Foundation for Cancer Research (NFCR) has listed the SQUID-based cancer imaging technology developed by MHTX's (OTCBB: MHTX) Senior Scientific subsidiary as a "2012 Research Breakthrough." Full release


Film Highlighting Collaborative Work by CINT & Senior Scientific (June 13, 2014)

Senior Scientific Mag Needle - Explains the technology for identifying cancer.

Bloomberg Podcast of Interview with Dr. Flynn (January 12, 2011)

MHTX Press Conference Video (October 15, 2010)

KSFR nano technology interview - Audio (October 14, 2010)

Manhattan Scientifics & The LANL Pushing Frontiers (March 25, 2009)

Manhattan Scientifics Press Conference (July 2, 2008)

Manhattan Scientifics Press Conference (July 1, 2008)

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MHTX News: Current Report Filing (8-k) 02/16/2017 04:48:16 PM
MHTX News: Current Report Filing (8-k) 12/01/2016 03:57:54 PM
MHTX News: Current Report Filing (8-k) 11/29/2016 10:47:17 AM
MHTX News: Quarterly Report (10-q) 11/15/2016 06:25:32 AM
MHTX News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 11/15/2016 06:25:30 AM
#5644   Everyone is starving except MARVIN!!! Saw on hunchboy 03/27/17 07:40:16 PM
#5641   Good to see the buyback is kicking in!! hunchboy 03/23/17 03:36:38 PM
#5640   Incredible stream of "alternate facts" from Manny and ssc 03/21/17 12:21:11 PM
#5639   Biggest WHOPPER is??? 1 The stock hunchboy 03/21/17 12:14:25 PM
#5638   sociopath or psychopath I am still trying to hunchboy 03/20/17 03:00:23 PM
#5637   That is the HYPE MO. In the mean hunchboy 03/10/17 08:24:24 AM
#5636   Had to be Maslow feeding him, sketchy history Hncher 03/09/17 10:54:08 AM
#5634   While he was probably spoon fed what to ssc 03/08/17 11:44:46 AM
#5633   Yea brought to you by Rustydog . No hunchboy 03/08/17 11:28:12 AM
#5632   Interesting how the biggest supporters of this stock ssc 03/07/17 11:53:45 PM
#5631   I remember we had quite a good time VerminHex 03/07/17 04:28:37 PM
#5630   Fantastic. Thanks so much for your help. ssc 03/07/17 11:51:46 AM
#5629   Post 1910. Hurry before it gets deleted. VerminHex 03/07/17 11:31:49 AM
#5628   I'm not sure if it was ever on VerminHex 03/07/17 11:06:03 AM
#5627   Thanks for the reply. Is this the ssc 03/07/17 07:33:14 AM
#5626   Oh, yeah. Psychic squid. It will read the VerminHex 03/06/17 09:28:50 PM
#5625   Anyone remember the posts that talked about an ssc 03/06/17 04:08:21 PM
#5624   Well We have anew KING of dilution in hunchboy 03/03/17 02:40:29 PM
#5623   I stand corrected. mason had right to exerciser hunchboy 02/15/17 09:19:20 AM
#5622   Takes one TO BE One ! You R klarino man 02/14/17 01:35:29 PM
#5621   Ok So mason got paid over a million hunchboy 02/14/17 11:21:57 AM
#5620   retard post hunchboy 02/14/17 11:17:12 AM
#5619   Why didn't you Bozos cash in @ 15-18 klarino man 02/14/17 09:53:54 AM
#5618   Those guy would never listen until they lost hunchboy 02/14/17 07:29:09 AM
#5617   "Me?I'm dishonest. And a dishonest man you can Jaybebaybe 02/13/17 09:40:25 PM
#5616   Looks like THE MARV got schooled by a ssc 02/13/17 04:28:34 PM
#5615   40 million less dilution is agood thing only hunchboy 02/13/17 03:27:40 PM
#5614   Ok mason and the boys agree to lend hunchboy 02/13/17 03:18:52 PM
#5613   You would think that having zero debt is hunchboy 02/13/17 02:47:31 PM
#5612   no clue, saw the news, posted the news, Diamond42 02/13/17 10:36:26 AM
#5611   So it looks like Mason got his money ssc 02/13/17 10:30:54 AM
#5610   MHTX forgot to say not only do they hunchboy 02/13/17 10:27:18 AM
#5609 Diamond42 02/13/17 09:17:49 AM
#5608   Someone please correct me if I am wrong, ssc 02/07/17 02:54:13 PM
#5607   What ? When exactly is the IPO . hunchboy 02/07/17 02:09:53 PM
#5606   ThingS got quiet.Any chance a buyer came in BRIAN111 02/02/17 12:13:11 PM
#5604   How about this alternative tidbit from the mhtx ssc 01/30/17 10:30:20 AM
#5603   Remember when mhtx's business plan was to license ssc 01/30/17 10:28:01 AM
#5601   How much at what price? hunchboy 01/30/17 10:07:28 AM
#5600   Great info. The 3.85 cent must be your hunchboy 01/30/17 10:06:20 AM
#5599   Accumulating here - klarino man 01/27/17 12:26:13 PM
#5598   Somethings up.No big boys selling. BRIAN111 01/25/17 07:46:55 PM
#5597   Go back and listen to the Proulx presentation ssc 01/04/17 11:38:15 AM
#5596   Not to be a wet blanket on your Hncher 01/04/17 09:31:59 AM
#5595   I meant "instrument" not "interment" eatbytes 01/02/17 04:11:10 PM
#5594   One item I saw on the Imagion webpage eatbytes 01/02/17 10:48:15 AM
#5593   Hncher, You are correct. I did some back-checking eatbytes 12/28/16 02:37:42 PM
#5592   This was a video created in June 12, Hncher 12/28/16 09:11:15 AM
#5591   Hncher, Listen close to the very end of their eatbytes 12/28/16 07:11:44 AM
#5590   Where does it say that eatbytes? How are Hncher 12/27/16 05:15:16 PM